Although DMARDs, steroids and biologic agents such as abatacept or TNF inhibitors significantly improve quality of life and prognosis for patients with RF-positive JIA there are still some patients who did not respond properly. The gene discussed is TNF; the disease is juvenile idiopathic arthritis.